ZG005

PreclinicalBiologic

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

ZG005 is one of 187 biologic programs targeting Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

186

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Cervical CarcinomaActive, not recruiting

Neuroendocrine CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Cervical CancerActive, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Cervical CarcinomaPhase 1/Phase 2

Active, not recruiting

Neuroendocrine CarcinomaPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Cervical CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Tafasitamab

Incyte

Preclinical

7 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

PEG-Intron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Recruiting

Neuroendocrine Carcinoma

NCT06372626

Q4 2026

Phase 2Recruiting

Hepatocellular Carcinoma

NCT06558227

Q2 2027

Phase 1/2Recruiting

Non-Small Cell Lung Cancer

NCT06903377

Phase 1/2Recruiting

Lymphoma

NCT06883526

Phase 2Recruiting

Patients With Advanced Solid Tumors

NCT06927687

Q3 2027

Phase 1/2Recruiting

Neuroendocrine Carcinoma

NCT07038096

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors3 trials

A Study of ZG005 in Patients With Advanced Solid Tumors

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06233292·484 enrolled

Study of ZG005 in Patients With Advanced Solid Tumors

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT06927687·100 enrolled

Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06938880·60 enrolled

Hepatocellular Carcinoma2 trials

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Unknown status·—·N/A·NCT06233994·30 enrolled

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT06558227·90 enrolled

Neuroendocrine Carcinoma2 trials

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT07038096·350 enrolled

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06372626·93 enrolled

Cervical Cancer1 trial

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT07080216·120 enrolled

Non-Small Cell Lung Cancer1 trial

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06903377·50 enrolled

5 more indications

Lymphoma1 trial

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06883526·60 enrolled

Cervical Carcinoma1 trial

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06241235·48 enrolled

Advanced Solid Tumor1 trial

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06239298·130 enrolled

Advanced Solid Tumors1 trial

Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

Not yet recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT07142837·153 enrolled

Advanced Biliary Tract Carcinoma1 trial

Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma

Not yet recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT07099547·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for ZG005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZG005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZG005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Zelgen Biopharmaceuticals Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

ZG005

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Patients With Advanced Solid Tumors3 trials

Hepatocellular Carcinoma2 trials

Neuroendocrine Carcinoma2 trials

Cervical Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Lymphoma1 trial

Cervical Carcinoma1 trial

Advanced Solid Tumor1 trial

Advanced Solid Tumors1 trial

Advanced Biliary Tract Carcinoma1 trial

References

Drug Info

Quick Facts

Related News